- Home
- GILD vs WFC Comparison
GILD vs WFC Comparison
Compare GILD & WFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GILD | WFC |
|---|---|---|
| Founded | 1987 | 1852 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.0B | 224.7B |
| IPO Year | 2003 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GILD | WFC |
|---|---|---|
| Price | $146.74 | $84.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 18 |
| Target Price | ★ $148.39 | $96.59 |
| AVG Volume (30 Days) | 6.4M | ★ 7.9M |
| Earning Date | 05-07-2026 | 04-14-2026 |
| Dividend Yield | ★ 2.55% | 2.21% |
| EPS Growth | ★ 1684.21 | 16.57 |
| EPS | N/A | ★ 3.60 |
| Revenue | $24,689,000,000.00 | ★ $85,063,000,000.00 |
| Revenue This Year | $4.68 | $11.08 |
| Revenue Next Year | $6.04 | $4.76 |
| P/E Ratio | ★ N/A | $23.29 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $108.46 | $72.78 |
| 52 Week High | $157.29 | $97.76 |
Technical Indicators
Market Signals| Indicator | GILD | WFC |
|---|---|---|
| Relative Strength Index (RSI) | 67.10 | 43.54 |
| Support Level | $142.93 | $83.77 |
| Resistance Level | $149.38 | $86.89 |
| Average True Range (ATR) | 3.96 | 1.62 |
| MACD | 1.15 | -0.56 |
| Stochastic Oscillator | 85.86 | 18.61 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About WFC Wells Fargo & Company
Wells Fargo is a premier, North American-focused banking titan that commands a $2.2 trillion balance sheet and the third-highest deposit market share in the United States. The bank uses a dense, expansive network of 4,093 branches to champion retail consumers and the middle market, where the firm has built a particularly strong reputation. Following the removal of its federal asset cap in 2025, the firm is set to deploy its legacy excess liquidity to expand each of its four segments: consumer & business lending, commercial banking, corporate & investment banking, and wealth & investment management.